Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Abstract

BackgroundHypertension and proteinuria are critically involved in the progression of chronic kidney disease. Despite treatment with renin angiotensin system inhibition, kidney function declines in many patients. Aldosterone excess is a risk factor for progression of kidney disease. Hyperkalaemia is a concern with the use of mineralocorticoid receptor antagonists. We aimed to determine whether the renal protective benefits of mineralocorticoid antagonists outweigh the risk of hyperkalaemia associated with this treatment in patients with chronic kidney disease.MethodsWe conducted a meta-analysis investigating renoprotective effects and risk of hyperkalaemia in trials of mineralocorticoid receptor antagonists in chronic kidney disease. Trials were identified from MEDLINE (1966–2014), EMBASE (1947–2014) and the Cochrane Clinical Trials Database. Unpublished summary data were obtained from investigators. We included randomised controlled trials, and the first period of randomised cross over trials lasting ≥4 weeks in adults.ResultsNineteen trials (21 study groups, 1 646 patients) were included. In random effects meta-analysis, addition of mineralocorticoid receptor antagonists to renin angiotensin system inhibition resulted in a reduction from baseline in systolic blood pressure (−5.7 [−9.0, −2.3] mmHg), diastolic blood pressure (−1.7 [−3.4, −0.1] mmHg) and glomerular filtration rate (−3.2 [−5.4, −1.0] mL/min/1.73 m2). Mineralocorticoid receptor antagonism reduced weighted mean protein/albumin excretion by 38.7 % but with a threefold higher relative risk of withdrawing from the trial due to hyperkalaemia (3.21, [1.19, 8.71]). Death, cardiovascular events and hard renal end points were not reported in sufficient numbers to analyse.ConclusionsMineralocorticoid receptor antagonism reduces blood pressure and urinary protein/albumin excretion with a quantifiable risk of hyperkalaemia above predefined study upper limit.Electronic supplementary materialThe online version of this article (doi:10.1186/s12882-016-0337-0) contains supplementary material, which is available to authorized users.

The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature

“…Two previously published meta-analysis studies published initially in 2009 and updated in 2014 demonstrated that the addition of MRA to RAS blockade reduced BP and proteinuria in CKD [77,78]. An updated meta-analysis that included previously unpublished data as well as including data from 3 studies which were not considered in the previous meta-analysis supported previous findings [79]. A total of 19 trials (1,646 patients) were included, of which 8 were done in patients with diabetic nephropathy.…”

Genetic Association of Albuminuria with Cardiometabolic Disease and Blood Pressure

“…NR3C2 encodes the mineralocorticoid receptor, and mineralocorticoid receptor antagonists such as spironolactone and eplerenone reduce albuminuria when added to other anti-hypertensive medications. 46,47 Mutations in COL4A4 and neighboring gene COL4A3 can cause autosomal Alport syndrome, which is characterized by kidney disease that can include proteinuria. 48 22 of the 33 loci (or their proxies R 2 > 0.8) were available in a smaller previously published genome-wide association study; 45 of these, 20 had a consistent direction of effect and 7 were nominally significant (p < 0.05, Table S3).…”

How to prevent the microvascular complications of type 2 diabetes beyond glucose control

“…110 Nineteen trials (with 1644 participants) were included, most in patients with CKD due to diabetic nephropathy. Similarly to the above, adding MRA to ACE inhibitor or ARB significantly improved blood pressure and albuminuria control but increased hyperkalemia.…”